Alkem Laboratories Ltd. Revenue Breakdown – NSE:ALKEM
NiveshIQ
NSE: ALKEM · Pharma
Alkem Laboratories Ltd.
₹5,672.50▲ ₹21.00 (+0.37%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ALKEM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Alkem Laboratories Ltd.
Alkem Laboratories Limited is a leading Indian pharmaceutical company with a diverse portfolio of branded generics, generic drugs, active pharmaceutical ingredients, biosimilars, and nutraceuticals. The company operates in various therapeutic areas, including anti-infective, gastroenterology, pain management, and more. Alkem Laboratories has a significant presence in India, the United States, and internationally, with a revenue of ₹14,712 Cr. Despite a 25% YoY decline in Q4 PAT to ₹251 cr, the company sees strong FY27 pipeline and upbeat revenue growth. Alkem Laboratories has a strong competitive position in the Indian market, with a robust product portfolio and a growing presence in the US and international markets. The company's growth outlook is driven by its expanding product portfolio
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹12,668 Cr +9.20% | ₹12,965 Cr +2.30% | ₹14,712 Cr +13.50% |
| EBITDA Margin | 17.73% | 19.38% | 24.39% |
| Net Profit | ₹1,811 Cr +79.80% | ₹2,215 Cr +22.30% | ₹2,351 Cr +6.10% |
| EPS | ₹150.19 | ₹181.12 | ₹192.51 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
AbbVie Seeks Block On Alkem Generic Constipation Drug
Alkem Laboratories Q1 Results: Earnings call scheduled for Aug 14
🔒
+ 3 more stories about Alkem Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹3, 603 Cr, PAT ₹251 Cr, EPS ₹19.77, EBITDA margin 19.9%. Growth context: revenue YoY +14.6%, revenue QoQ -3.6%, PAT QoQ -61.5%. Street verdict: miss, revenue surprise +0.6%, PAT surprise -8.9%.
Management commentary highlights key growth drivers, including product launches, approvals, and therapy-mix improvement,...
FY26 (last completed FY): revenue ₹14, 712 Cr, PAT ₹2, 351 Cr, EBITDA margin 24.4%, EPS ₹192.51. Year-on-year: revenue Y...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ALKEM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ALKEM alongside your other holdings
Unlock full ALKEM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Alkem Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Alkem Laboratories Ltd. (ALKEM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Alkem Laboratories Ltd.?
Alkem Laboratories Ltd. operates in the Pharma sector with a market capitalisation of ₹6,546,183.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.